New fatty liver drug tested in humans for first time
NCT ID NCT05599945
First seen Nov 01, 2025 · Last updated Jun 10, 2026 · Updated 31 times
Summary
This early-stage study tested a new medicine, NNC0581-0001, in 48 healthy adults and people with fatty liver (hepatic steatosis). The main goal was to check safety and how the drug moves through the body after a single injection. Participants were randomly assigned to receive the drug or a placebo. The study lasted about 58 weeks and was not designed to treat the condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Parexel CPRU, Level 7
Harrow, Middlesex, HA1 3UJ, United Kingdom
-
Parexel Research Unit
Harrow, Middlesex, HA1 3UJ, United Kingdom
Conditions
Explore the condition pages connected to this study.